The European Union's medical regulator has approved the use of Novo Nordisk's popular weight reduction medication Wegovy to prevent the escalation of major cardiac events in persons who are overweight or obese.
After analysing the results of the highly monitored SELECT study, the Danish pharmaceutical behemoth announced on Thursday that the European Medical Agency has issued a “positive opinion” on the label expansion, allowing for further applications for the medication.
Published in August 2023, the SELECT study, which was supported by Novo Nordisk, revealed that the active component of Wegovy and Ozempic, semaglutide, reduced the risk of major cardiovascular events by 20% when compared to a placebo.
“We believe that the recommendation to update the EMA label for Wegovy is a significant milestone for people living with cardiovascular disease and obesity,” Novo Nordisk’s executive vice president and head of development, Martin Holst Lange, said in a statement.
“The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events.”
According to the business, the label update also contains data from the SELECT study that demonstrated a 15% risk reduction in cardiovascular mortality and a 19% risk reduction in death from any cause when compared to cases when a placebo was administered.
Within a month, Novo Nordisk stated, the label modification would be put into effect.
It comes after comparable actions taken by the UK's medical authorities, which authorised the use of Wegovy on Tuesday to lower the risk of adult overweight and obese patients experiencing major cardiac issues or strokes.
As competition in the industry heats up, the U.S. Food and medication Administration authorised the medication in March for these kinds of uses as well, increasing the very popular medicine's use cases.
The massive Swiss pharmaceutical company Roche said on Thursday that a range of medications intended to counteract the consequences of obesity will include its Wegovy competitor weight reduction pills.
Positive early stage trial findings from the company's two weight reduction medication prospects were hailed by CEO Thomas Schinecker, who noted that they showed "best in disease potential." He went on to say that they will be a part of a larger portfolio designed to set the Swiss business apart from rivals in the expanding market for obesity medications.
(Source:www.bloomberg.com)
After analysing the results of the highly monitored SELECT study, the Danish pharmaceutical behemoth announced on Thursday that the European Medical Agency has issued a “positive opinion” on the label expansion, allowing for further applications for the medication.
Published in August 2023, the SELECT study, which was supported by Novo Nordisk, revealed that the active component of Wegovy and Ozempic, semaglutide, reduced the risk of major cardiovascular events by 20% when compared to a placebo.
“We believe that the recommendation to update the EMA label for Wegovy is a significant milestone for people living with cardiovascular disease and obesity,” Novo Nordisk’s executive vice president and head of development, Martin Holst Lange, said in a statement.
“The SELECT data demonstrated that in addition to helping people manage their weight, Wegovy has the potential to protect lives by reducing the risks of major adverse cardiovascular events.”
According to the business, the label update also contains data from the SELECT study that demonstrated a 15% risk reduction in cardiovascular mortality and a 19% risk reduction in death from any cause when compared to cases when a placebo was administered.
Within a month, Novo Nordisk stated, the label modification would be put into effect.
It comes after comparable actions taken by the UK's medical authorities, which authorised the use of Wegovy on Tuesday to lower the risk of adult overweight and obese patients experiencing major cardiac issues or strokes.
As competition in the industry heats up, the U.S. Food and medication Administration authorised the medication in March for these kinds of uses as well, increasing the very popular medicine's use cases.
The massive Swiss pharmaceutical company Roche said on Thursday that a range of medications intended to counteract the consequences of obesity will include its Wegovy competitor weight reduction pills.
Positive early stage trial findings from the company's two weight reduction medication prospects were hailed by CEO Thomas Schinecker, who noted that they showed "best in disease potential." He went on to say that they will be a part of a larger portfolio designed to set the Swiss business apart from rivals in the expanding market for obesity medications.
(Source:www.bloomberg.com)
Homepage
Send to a friend
Printable version
Share
